Cargando…

A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

SIMPLE SUMMARY: AML is a common form of blood cancer in adults. This study was undertaken to evaluate if AML patients who have failed the available standard treatment options could tolerate and potentially benefit from a new form of therapy. This new therapy activates patients’ own immune system aga...

Descripción completa

Detalles Bibliográficos
Autores principales:	Uckun, Fatih M., Lin, Tara L., Mims, Alice S., Patel, Prapti, Lee, Cynthia, Shahidzadeh, Anoush, Shami, Paul J., Cull, Elizabeth, Cogle, Christopher R., Watts, Justin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8394899/ https://www.ncbi.nlm.nih.gov/pubmed/34439266 http://dx.doi.org/10.3390/cancers13164113

Ejemplares similares

Post-hoc Analysis of Pharmacodynamics and Single-Agent Activity of CD3xCD123 Bispecific Antibody APVO436 in Relapsed/Refractory AML and MDS Resistant to HMA or Venetoclax Plus HMA
por: Watts, Justin, et al.
Publicado: (2022)

Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436
por: Uckun, Fatih M., et al.
Publicado: (2021)

CD123-Directed Bispecific Antibodies for Targeting MDS Clones and Immunosuppressive Myeloid-Derived Suppressor Cells (MDSC) in High-Risk Adult MDS Patients
por: Uckun, Fatih M., et al.
Publicado: (2021)

APVO210: A Bispecific Anti-CD86-IL-10 Fusion Protein (ADAPTIR™) to Induce Antigen-Specific T Regulatory Type 1 Cells
por: Pellerin, Laurence, et al.
Publicado: (2018)

CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL
por: Reusing, Sarah B., et al.
Publicado: (2021)

Bispecific antibody targeting TROP2xCD3 suppresses tumor growth of triple negative breast cancer
por: Liu, Huicheng, et al.
Publicado: (2021)

Correction to: CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL
por: Reusing, Sarah B., et al.
Publicado: (2021)

A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL
por: Mehta, Naveen K, et al.
Publicado: (2022)

CD47xCD19 bispecific antibody triggers recruitment and activation of innate immune effector cells in a B-cell lymphoma xenograft model
por: Chauchet, Xavier, et al.
Publicado: (2022)

Selinexor Sensitizes TRAIL-R2-Positive TNBC Cells to the Activity of TRAIL-R2xCD3 Bispecific Antibody
por: Martini, Silvia, et al.
Publicado: (2020)

IgG-based B7-H3xCD3 bispecific antibody for treatment of pancreatic, hepatic and gastric cancer
por: Lutz, Martina S., et al.
Publicado: (2023)

P437: EFFECTIVE IMMUNOTHERAPY OF PEDIATRIC T(8;21) ACUTE MYELOID LEUKEMIA BY REPURPOSING CD3XCD19 TARGETING BISPECIFIC ANTIBODIES
por: Wijnen, Noa, et al.
Publicado: (2023)

Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells
por: Wathikthinnakon, Methi, et al.
Publicado: (2022)

The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34(+)CD123(+) cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donors
por: Mani, Rajeswaran, et al.
Publicado: (2018)

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial
por: Thieblemont, Catherine, et al.
Publicado: (2023)

CD19xCD3 DART protein mediates human B-cell depletion in vivo in humanized BLT mice
por: Tsai, Perry, et al.
Publicado: (2016)

Constitutive Function of the Ikaros Transcription Factor in Primary Leukemia Cells from Pediatric Newly Diagnosed High-Risk and Relapsed B-precursor ALL Patients
por: Uckun, Fatih M., et al.
Publicado: (2013)

P815: HIGH VALENCY OF IGM-2644, A CD38XCD3 IGM BISPECIFIC T CELL ENGAGER, DISPLACES DARATUMUMAB BINDING AND INDUCES POTENT MULTIPLE MYELOMA CELL KILLING
por: Hart, Kevin C., et al.
Publicado: (2023)

Engineering tandem CD33xCD146 CAR CIK (cytokine-induced killer) cells to target the acute myeloid leukemia niche
por: Alberti, Gaia, et al.
Publicado: (2023)

Preclinical Evidence of an Allogeneic Dual CD20xCD22 CAR to Target a Broad Spectrum of Patients with B-cell Malignancies
por: Aranda-Orgilles, Beatriz, et al.
Publicado: (2023)

PB2100: MANAGEMENT OF RELAPSED / REFRACTORY (R/R) B-CELL NON HODGKIN LYMPHOMA (B-NHL) WITH ANTI-CD20XCD3 BISPECIFIC ANTIBODY GLOFITAMAB. A SINGLE CENTER EXPERIENCE.
por: Giatra, C., et al.
Publicado: (2022)

P1276: DOSE RESPONSE PROFILE OF IGM-2323, A CD20XCD3 IGM BISPECIFIC T CELL ENGAGER, IN TRANSLATIONAL MODELS SUPPORTS PHASE 2 DOSE SELECTION IN NON-HODGKIN’S LYMPHOMA
por: Leabman, M. K., et al.
Publicado: (2022)

Daunorubicin-Loaded CdTe QDs Conjugated with Anti-CD123 mAbs: A Novel Delivery System for Myelodysplastic Syndromes Treatment
por: Guo, Dan, et al.
Publicado: (2020)

Incidence and Burden of the Myelodysplastic Syndromes
por: Cogle, Christopher R.
Publicado: (2015)

DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing
por: Engelberts, Patrick J., et al.
Publicado: (2020)

A Phase 1B Clinical Study of Combretastatin A1 Diphosphate (OXi4503) and Cytarabine (ARA-C) in Combination (OXA) for Patients with Relapsed or Refractory Acute Myeloid Leukemia
por: Uckun, Fatih M., et al.
Publicado: (2019)

CD22 Exon 12 Deletion as an Independent Predictor of Poor Treatment Outcomes in B-ALL
por: Qazi, Sanjive, et al.
Publicado: (2023)

CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells
por: Martens, Anne W J, et al.
Publicado: (2020)

Diagnostic Challenges of CD4(+)/CD56(+)/CD123(+) hematological neoplasms
por: Thiago, Leandro S., et al.
Publicado: (2013)

Séminaire Bourbaki : exposés 436–452
por: Collective
Publicado: (1975)

Development Of [(211)At]Astatine-Based Anti-CD123 Radioimmunotherapy For Acute Leukemias and Other CD123+ Malignancies
por: Laszlo, George S., et al.
Publicado: (2022)

Correction: CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells
Publicado: (2021)

Computational Modeling and Treatment Identification in the Myelodysplastic Syndromes
por: Drusbosky, Leylah M., et al.
Publicado: (2017)

Anti-CD22/CD20 Bispecific Antibody with Enhanced Trogocytosis for Treatment of Lupus
por: Rossi, Edmund A., et al.
Publicado: (2014)

Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells
por: Cai, Tianyu, et al.
Publicado: (2022)

SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells
por: Tahk, Siret, et al.
Publicado: (2021)

Identification and targeting of CD22ΔE12 as a molecular RNAi target to overcome drug resistance in high-risk B-lineage leukemias and lymphomas
por: Uckun, Fatih M., et al.
Publicado: (2018)

Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using cross-over dual-variable domain (CODV) format for acute myeloid leukemia (AML) treatment
por: Bonnevaux, Hélène, et al.
Publicado: (2021)

Targeting immunotherapy for bladder cancer by using anti-CD3 × CD155 bispecific antibody
por: Ma, Wanru, et al.
Publicado: (2019)

Survival outcomes of CD34(+)CD38(−)LSCs and their expression of CD123 in adult AML patients
por: Zahran, Asmaa M., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0c056lbao98hjbikn7aohousvk